View of statins as antimicrobials in cardiovascular risk modification

被引:22
|
作者
Kozarov, Emil [1 ,2 ]
Padro, Teresa [1 ]
Badimon, Lina [1 ,3 ]
机构
[1] Biomed Res Inst St Pau IIB St Pau, Cardiovasc Res Ctr CSIC ICCC, Barcelona 08025, Spain
[2] Columbia Univ, Med Ctr, New York, NY 10032 USA
[3] UAB, Cardiovasc Res Chair, Barcelona, Spain
关键词
Atherosclerosis; Statins; Microbial infection; Inflammation; CHLAMYDIA-PNEUMONIAE INFECTION; ARTERIAL OCCLUSIVE DISEASE; CORONARY-HEART-DISEASE; ACUTE-MYOCARDIAL-INFARCTION; ABDOMINAL AORTIC-ANEURYSMS; SECONDARY PREVENTION TRIAL; RANDOMIZED CLINICAL-TRIAL; A REDUCTASE-ACTIVITY; C-REACTIVE PROTEIN; DOUBLE-BLIND;
D O I
10.1093/cvr/cvu058
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Atherosclerosis is a complex arterial pathological development underlying heart attack and stroke and a leading cause of death in developed and now also in developing countries. The primary processes that lead to the inflammatory lipid-laden proliferative lesion, obstructing the blood flow, and referred to as atherosclerotic plaque are dyslipidaemia and inflammation. Here, we will review one of the most efficient classes of drugs indicated for management of cardiovascular disease (CVD), statins. We will assess their pleiotropic effects that emerged from CVD applications, focusing this review specifically on plausible antimicrobial activity. Only recently gaining strength, the recognition of possible antibacterial activity may extend the statin applicability for vascular as well as to other critical inflammatory conditions.
引用
收藏
页码:362 / 374
页数:13
相关论文
共 50 条
  • [31] Statins for primary prevention: problems with cardiovascular-risk estimation?
    Željko Reiner
    Nature Reviews Cardiology, 2013, 10 : 547 - 547
  • [32] LDL cholesterol response to statins and future risk of cardiovascular disease
    Akyea, Ralph Kwame
    Kai, Joe
    Qureshi, Nadeem
    Iyen, Barbara
    Weng, Stephen F.
    HEART, 2019, 105 (16) : 1290 - 1291
  • [33] Management of high cardiovascular risk patients treated with statins in France
    Dallongeville, J.
    Thomas-Delecourt, F.
    Morand, F.
    EUROPEAN HEART JOURNAL, 2010, 31 : 813 - 813
  • [34] NICE recommends wider use of statins to cut cardiovascular risk
    O'Dowd, Adrian
    BMJ-BRITISH MEDICAL JOURNAL, 2023, 380 : p89
  • [35] Statins Accelerate Coronary Calcification and Reduce the Risk of Cardiovascular Events
    Zhang, Xinyu
    Miao, Dongxia
    Hu, Yue
    Jie, Xiao
    Lei, Wang
    Ji, Xiaoping
    CARDIOLOGY IN REVIEW, 2023, 31 (06) : 293 - 298
  • [36] Targeting cardiovascular risk in rheumatoid arthritis: a dual role for statins
    Radjesh J. Bisoendial
    Erik S. G. Stroes
    John J. P. Kastelein
    Paul Peter Tak
    Nature Reviews Rheumatology, 2010, 6 : 157 - 164
  • [37] A systematic review of cost effectiveness of statins in cardiovascular risk management
    Franco, O
    Bonneux, L
    VALUE IN HEALTH, 2003, 6 (06) : 669 - 669
  • [38] Statins in Chronic Kidney Disease: Cardiovascular Risk and Kidney Function
    Deedwania, Prakash C.
    POSTGRADUATE MEDICINE, 2014, 126 (01) : 29 - 36
  • [39] Targeting cardiovascular risk in rheumatoid arthritis: a dual role for statins
    Bisoendial, Radjesh J.
    Stroes, Erik S. G.
    Kastelein, John J. P.
    Tak, Paul Peter
    NATURE REVIEWS RHEUMATOLOGY, 2010, 6 (03) : 157 - 164
  • [40] About cardiovascular risk assessment in the new clinical trials with statins
    Luján, FM
    Justel, MB
    Alberich, RS
    Gallisà, JB
    MEDICINA CLINICA, 2004, 122 (14): : 559 - 559